Management, in-hospital outcomes and screening of extra-coronary vascular abnormalities
| . | <65 years old (263 patients) . | ≥65 years old (55 patients) . | P-value . |
|---|---|---|---|
| Initial management | 0.02 | ||
| Conservative | 198 (75) | 49 (89) | |
| Percutaneous coronary intervention (PCI) | 65 (25) | 6 (11) | |
| PCI success | 52 (80) | 5 (83) | 0.90 |
| Troponin I rise | 105 (96) | 28 (100) | 0.30 |
| Troponin T rise | 133 (96) | 20 (100) | 0.34 |
| Creatine kinase rise | 91 (35) | 16 (29) | 0.75 |
| Ejection fraction (EF) | 57 ± 9 | 58 ± 12 | 0.85 |
| EF <50% | 31 (14) | 7 (17) | 0.62 |
| Left ventricle wall motion abnormalities | 140 (59) | 28 (62) | 0.67 |
| Hospital length of stay (days) | 4 (3–6) | 3 (3–6) | 0.28 |
| Discharge treatment | |||
| Aspirin | 245 (94) | 44 (83) | <0.01 |
| Clopidogrel | 103 (40) | 26 (49) | 0.20 |
| Ticagrelor | 53 (20) | 6 (11) | 0.12 |
| Prasugrel | 8 (3) | 2 (4) | 0.79 |
| DAPT | 157 (60) | 29 (53) | 0.34 |
| OAC | 15 (6) | 7 (13) | 0.06 |
| Beta-blocker | 202 (78) | 45 (85) | 0.24 |
| ACEIs/ARB | 122 (47) | 38 (72) | <0.01 |
| Statins | 199 (77) | 48 (91) | 0.02 |
| Nitrates | 27 (10) | 8 (15) | 0.32 |
| Calcium channel blockers | 20 (8) | 5 (9) | 0.67 |
| In-hospital MACE | 21 (8) | 4 (7) | 0.86 |
| Death | 2 (0.8) | 2 (3.6) | 0.08 |
| Myocardial reinfarction | 9 (3.4) | 1 (1.8) | 0.54 |
| Unplanned coronary angiogram | 18 (6.8) | 2 (3.6) | 0.37 |
| Congestive heart failure | 1 (0.4) | 1 (1.8) | 0.22 |
| Screening of EVA | 80 (30) | 13 (24) | 0.23 |
| Presence of EVA (including FMD) | 27/80 (34) | 4/13 (31) | 0.93 |
| . | <65 years old (263 patients) . | ≥65 years old (55 patients) . | P-value . |
|---|---|---|---|
| Initial management | 0.02 | ||
| Conservative | 198 (75) | 49 (89) | |
| Percutaneous coronary intervention (PCI) | 65 (25) | 6 (11) | |
| PCI success | 52 (80) | 5 (83) | 0.90 |
| Troponin I rise | 105 (96) | 28 (100) | 0.30 |
| Troponin T rise | 133 (96) | 20 (100) | 0.34 |
| Creatine kinase rise | 91 (35) | 16 (29) | 0.75 |
| Ejection fraction (EF) | 57 ± 9 | 58 ± 12 | 0.85 |
| EF <50% | 31 (14) | 7 (17) | 0.62 |
| Left ventricle wall motion abnormalities | 140 (59) | 28 (62) | 0.67 |
| Hospital length of stay (days) | 4 (3–6) | 3 (3–6) | 0.28 |
| Discharge treatment | |||
| Aspirin | 245 (94) | 44 (83) | <0.01 |
| Clopidogrel | 103 (40) | 26 (49) | 0.20 |
| Ticagrelor | 53 (20) | 6 (11) | 0.12 |
| Prasugrel | 8 (3) | 2 (4) | 0.79 |
| DAPT | 157 (60) | 29 (53) | 0.34 |
| OAC | 15 (6) | 7 (13) | 0.06 |
| Beta-blocker | 202 (78) | 45 (85) | 0.24 |
| ACEIs/ARB | 122 (47) | 38 (72) | <0.01 |
| Statins | 199 (77) | 48 (91) | 0.02 |
| Nitrates | 27 (10) | 8 (15) | 0.32 |
| Calcium channel blockers | 20 (8) | 5 (9) | 0.67 |
| In-hospital MACE | 21 (8) | 4 (7) | 0.86 |
| Death | 2 (0.8) | 2 (3.6) | 0.08 |
| Myocardial reinfarction | 9 (3.4) | 1 (1.8) | 0.54 |
| Unplanned coronary angiogram | 18 (6.8) | 2 (3.6) | 0.37 |
| Congestive heart failure | 1 (0.4) | 1 (1.8) | 0.22 |
| Screening of EVA | 80 (30) | 13 (24) | 0.23 |
| Presence of EVA (including FMD) | 27/80 (34) | 4/13 (31) | 0.93 |
Categorical variables are expressed as n (%); quantitative variables are expressed as mean (SD).
ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blockers; DAPT, dual antiplatelet therapy; EVA, extra-coronary vascular abnormalities; FMD, fibromuscular dysplasia; MACE, major adverse cardiac event; OAC, oral anticoagulation.
Management, in-hospital outcomes and screening of extra-coronary vascular abnormalities
| . | <65 years old (263 patients) . | ≥65 years old (55 patients) . | P-value . |
|---|---|---|---|
| Initial management | 0.02 | ||
| Conservative | 198 (75) | 49 (89) | |
| Percutaneous coronary intervention (PCI) | 65 (25) | 6 (11) | |
| PCI success | 52 (80) | 5 (83) | 0.90 |
| Troponin I rise | 105 (96) | 28 (100) | 0.30 |
| Troponin T rise | 133 (96) | 20 (100) | 0.34 |
| Creatine kinase rise | 91 (35) | 16 (29) | 0.75 |
| Ejection fraction (EF) | 57 ± 9 | 58 ± 12 | 0.85 |
| EF <50% | 31 (14) | 7 (17) | 0.62 |
| Left ventricle wall motion abnormalities | 140 (59) | 28 (62) | 0.67 |
| Hospital length of stay (days) | 4 (3–6) | 3 (3–6) | 0.28 |
| Discharge treatment | |||
| Aspirin | 245 (94) | 44 (83) | <0.01 |
| Clopidogrel | 103 (40) | 26 (49) | 0.20 |
| Ticagrelor | 53 (20) | 6 (11) | 0.12 |
| Prasugrel | 8 (3) | 2 (4) | 0.79 |
| DAPT | 157 (60) | 29 (53) | 0.34 |
| OAC | 15 (6) | 7 (13) | 0.06 |
| Beta-blocker | 202 (78) | 45 (85) | 0.24 |
| ACEIs/ARB | 122 (47) | 38 (72) | <0.01 |
| Statins | 199 (77) | 48 (91) | 0.02 |
| Nitrates | 27 (10) | 8 (15) | 0.32 |
| Calcium channel blockers | 20 (8) | 5 (9) | 0.67 |
| In-hospital MACE | 21 (8) | 4 (7) | 0.86 |
| Death | 2 (0.8) | 2 (3.6) | 0.08 |
| Myocardial reinfarction | 9 (3.4) | 1 (1.8) | 0.54 |
| Unplanned coronary angiogram | 18 (6.8) | 2 (3.6) | 0.37 |
| Congestive heart failure | 1 (0.4) | 1 (1.8) | 0.22 |
| Screening of EVA | 80 (30) | 13 (24) | 0.23 |
| Presence of EVA (including FMD) | 27/80 (34) | 4/13 (31) | 0.93 |
| . | <65 years old (263 patients) . | ≥65 years old (55 patients) . | P-value . |
|---|---|---|---|
| Initial management | 0.02 | ||
| Conservative | 198 (75) | 49 (89) | |
| Percutaneous coronary intervention (PCI) | 65 (25) | 6 (11) | |
| PCI success | 52 (80) | 5 (83) | 0.90 |
| Troponin I rise | 105 (96) | 28 (100) | 0.30 |
| Troponin T rise | 133 (96) | 20 (100) | 0.34 |
| Creatine kinase rise | 91 (35) | 16 (29) | 0.75 |
| Ejection fraction (EF) | 57 ± 9 | 58 ± 12 | 0.85 |
| EF <50% | 31 (14) | 7 (17) | 0.62 |
| Left ventricle wall motion abnormalities | 140 (59) | 28 (62) | 0.67 |
| Hospital length of stay (days) | 4 (3–6) | 3 (3–6) | 0.28 |
| Discharge treatment | |||
| Aspirin | 245 (94) | 44 (83) | <0.01 |
| Clopidogrel | 103 (40) | 26 (49) | 0.20 |
| Ticagrelor | 53 (20) | 6 (11) | 0.12 |
| Prasugrel | 8 (3) | 2 (4) | 0.79 |
| DAPT | 157 (60) | 29 (53) | 0.34 |
| OAC | 15 (6) | 7 (13) | 0.06 |
| Beta-blocker | 202 (78) | 45 (85) | 0.24 |
| ACEIs/ARB | 122 (47) | 38 (72) | <0.01 |
| Statins | 199 (77) | 48 (91) | 0.02 |
| Nitrates | 27 (10) | 8 (15) | 0.32 |
| Calcium channel blockers | 20 (8) | 5 (9) | 0.67 |
| In-hospital MACE | 21 (8) | 4 (7) | 0.86 |
| Death | 2 (0.8) | 2 (3.6) | 0.08 |
| Myocardial reinfarction | 9 (3.4) | 1 (1.8) | 0.54 |
| Unplanned coronary angiogram | 18 (6.8) | 2 (3.6) | 0.37 |
| Congestive heart failure | 1 (0.4) | 1 (1.8) | 0.22 |
| Screening of EVA | 80 (30) | 13 (24) | 0.23 |
| Presence of EVA (including FMD) | 27/80 (34) | 4/13 (31) | 0.93 |
Categorical variables are expressed as n (%); quantitative variables are expressed as mean (SD).
ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blockers; DAPT, dual antiplatelet therapy; EVA, extra-coronary vascular abnormalities; FMD, fibromuscular dysplasia; MACE, major adverse cardiac event; OAC, oral anticoagulation.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
